Tislelizumab was approved by the China
National Medical Products Administration on December 27, 2019 to treat patients with classical
Hodgkin’s lymphoma (cHL) who have received at least two prior therapies[8] and on April 10, 2020 to treat patients with locally advanced or metastatic urothelial carcinoma (UC) with PD-L1 high expression whose disease progressed during or following platinum-containing
chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.[9]
Phase 1 trial in patients with advanced solid tumors (NCT02407990)[10]
Phase 3 trial comparing tislelizumab with docetaxel in the second- or third-line setting in patients with non-small cell lung cancer (NSCLC) (NCT03358875)[11]
Phase 3 trial comparing tislelizumab with sorafenib as first-line treatment for patients with hepatocellular carcinoma (HCC) (NCT03412773)[12]
Phase 2 trial in patients with previously treated unresectable HCC (NCT03419897)[13]
Phase 3 trial comparing tislelizumab with chemotherapy as second-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC) (NCT03430843)[14]
Phase 3 trial of tislelizumab in combination with chemotherapy versus chemotherapy as first-line treatment for patients with advanced squamous NSCLC (NCT03594747)[15]
Phase 3 trial of tislelizumab in combination with chemotherapy versus chemotherapy as first-line treatment for patients with advanced non-squamous NSCLC (NCT03663205)[16]
Phase 2 trial in patients with MSI-H/dMMR solid tumors (NCT03736889)[17]
Phase 3 trial of tislelizumab combined with chemotherapy versus placebo combined with chemotherapy as first-line treatment for patients with gastric cancer (NCT03777657)[18]
Phase 3 trial of tislelizumab in combination with chemotherapy as first-line treatment for patients with ESCC (NCT03783442)[19]
Phase 3 trial of tislelizumab combined with chemotherapy versus placebo combined with chemotherapy as first-line treatment in patients with nasopharyngeal cancer (NCT03924986)[20]
Phase 3 trial of tislelizumab versus placebo in combination with chemoradiotherapy in patients with localized ESCC (NCT03957590)[21]
Phase 3 trial in patients with locally advanced or metastatic urothelial carcinoma (NCT03967977)[22]
Phase 2 trial in patients with locally advanced or metastatic urothelial bladder cancer (NCT04004221)[23]
Phase 3 trial of tislelizumab combined with platinum and etoposide versus placebo combined with platinum and etoposide in patients with extensive-stage small cell lung cancer (NCT04005716)[24]
Tislelizumab was approved by the China
National Medical Products Administration on December 27, 2019 to treat patients with classical
Hodgkin’s lymphoma (cHL) who have received at least two prior therapies[8] and on April 10, 2020 to treat patients with locally advanced or metastatic urothelial carcinoma (UC) with PD-L1 high expression whose disease progressed during or following platinum-containing
chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.[9]
Phase 1 trial in patients with advanced solid tumors (NCT02407990)[10]
Phase 3 trial comparing tislelizumab with docetaxel in the second- or third-line setting in patients with non-small cell lung cancer (NSCLC) (NCT03358875)[11]
Phase 3 trial comparing tislelizumab with sorafenib as first-line treatment for patients with hepatocellular carcinoma (HCC) (NCT03412773)[12]
Phase 2 trial in patients with previously treated unresectable HCC (NCT03419897)[13]
Phase 3 trial comparing tislelizumab with chemotherapy as second-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC) (NCT03430843)[14]
Phase 3 trial of tislelizumab in combination with chemotherapy versus chemotherapy as first-line treatment for patients with advanced squamous NSCLC (NCT03594747)[15]
Phase 3 trial of tislelizumab in combination with chemotherapy versus chemotherapy as first-line treatment for patients with advanced non-squamous NSCLC (NCT03663205)[16]
Phase 2 trial in patients with MSI-H/dMMR solid tumors (NCT03736889)[17]
Phase 3 trial of tislelizumab combined with chemotherapy versus placebo combined with chemotherapy as first-line treatment for patients with gastric cancer (NCT03777657)[18]
Phase 3 trial of tislelizumab in combination with chemotherapy as first-line treatment for patients with ESCC (NCT03783442)[19]
Phase 3 trial of tislelizumab combined with chemotherapy versus placebo combined with chemotherapy as first-line treatment in patients with nasopharyngeal cancer (NCT03924986)[20]
Phase 3 trial of tislelizumab versus placebo in combination with chemoradiotherapy in patients with localized ESCC (NCT03957590)[21]
Phase 3 trial in patients with locally advanced or metastatic urothelial carcinoma (NCT03967977)[22]
Phase 2 trial in patients with locally advanced or metastatic urothelial bladder cancer (NCT04004221)[23]
Phase 3 trial of tislelizumab combined with platinum and etoposide versus placebo combined with platinum and etoposide in patients with extensive-stage small cell lung cancer (NCT04005716)[24]